

119TH CONGRESS
1ST SESSION

H. R. 586

To direct the Secretary of Veterans Affairs to study and report on the prevalence of cholangiocarcinoma in veterans who served in the Vietnam theater of operations during the Vietnam era, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

JANUARY 21, 2025

Mr. LALOTA (for himself, Mr. RYAN, Mr. FITZPATRICK, Mr. DAVIS of North Carolina, Mr. GOTTHEIMER, and Mr. CISCOMANI) introduced the following bill; which was referred to the Committee on Veterans' Affairs

A BILL

To direct the Secretary of Veterans Affairs to study and report on the prevalence of cholangiocarcinoma in veterans who served in the Vietnam theater of operations during the Vietnam era, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Vietnam Veterans
5 Liver Fluke Cancer Study Act”.

1 **SEC. 2. STUDY ON THE PREVALENCE OF**
2 **CHOLANGIOCARCINOMA IN VETERANS WHO**
3 **SERVED IN THE VIETNAM THEATER OF OPER-**
4 **ATIONS DURING THE VIETNAM ERA.**

5 (a) EPIDEMIOLOGICAL STUDY.—Not later than 120
6 days after the date of enactment of this Act, the Secretary
7 of Veterans Affairs, in consultation with the Director of
8 the Centers for Disease Control and Prevention of the De-
9 partment of Health and Human Services, shall commence
10 an epidemiological study on the prevalence of
11 cholangiocarcinoma in covered veterans of the Vietnam
12 era, using data from the Veterans Affairs Central Cancer
13 Registry and the National Program of Cancer Registries.
14 The study shall include—

15 (1) an identification of the rate of incidence of
16 cholangiocarcinoma in covered veterans of the Viet-
17 nam era and in residents of the United States, from
18 the beginning of the Vietnam era to the date of en-
19 actment of this Act; and

20 (2) for each of the groups specified in para-
21 graph (1), an identification of the percentage of in-
22 dividuals with cholangiocarcinoma by various demo-
23 graphic characteristics, including by age, gender,
24 race, ethnicity, and the geographic location of the
25 patient at the time of diagnosis.

26 (b) REPORTS TO CONGRESS.—

1 (1) INITIAL REPORT.—Not later than one year
2 after the completion of the study under subsection
3 (a), the Secretary shall submit to Congress a report
4 containing—

5 (A) the results of the study under sub-
6 section (a); and

7 (B) recommendations for administrative or
8 legislative actions required to address issues
9 identified in the study under subsection (a).

10 (2) FOLLOW-UP REPORTS.—The Secretary shall
11 periodically submit to the Congress a follow-up re-
12 ports, as determined by the Secretary, to provide up-
13 dates to the information included in the initial re-
14 port under paragraph (1) and information collected
15 pursuant to subsection (c).

16 (c) CONTINUED TRACKING OF
17 CHOLANGIOCARCINOMA IN COVERED VETERANS OF THE
18 VIETNAM ERA.—The Secretary shall track the prevalence
19 of cholangiocarcinoma in covered veterans of the Vietnam
20 era using the Veterans Affairs Central Cancer Registry,
21 and provide such information to Congress in follow-up re-
22 ports submitted under subsection (b)(2).

23 (d) DEFINITIONS.—In this section:

1 (1) The term “Vietnam era” has the meaning
2 given such term in section 101 of title 38, United
3 States Code.

4 (2) The term “covered veterans of the Vietnam
5 era” means veterans who served in the Vietnam the-
6 ater of operations during the Vietnam era.

○